Research & Development
PharmaJet Selected to Deliver Scancell COVID-19 DNA Vaccines
15 September 2021 - - US-based needle-free injection technology provider PharmaJet's partner, biopharmaceutical company Scancell, has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2, the company said.

The vaccines will be exclusively administered using the PharmaJet Tropis and PharmaJet Stratis Needle-free Injection Systems.

Scancell's COVIDITY-001 study, including the use of the two PharmaJet systems, has been approved by the South African regulatory authority.

This program is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University.

Preclinical studies have confirmed that PharmaJet delivery of the COVIDITY vaccines induces potent immune responses against both S and N antigens.

PharmaJet's mission is to improve people's lives through needle-free technology. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use.

The Stratis System has US FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis System has CE Mark and WHO PQS certification for intradermal injections.

Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody, Moditope and AvidiMab platforms.

In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective, and scalable vaccine to induce both durable T cell responses and virus neutralizing antibodies against SARS-Cov-2, the virus that causes COVID-19.


Related Headlines